AstraZeneca Vaccine not recommended for Under 55s in Canada
Canadian Medical experts on Monday recommended stopping the use of the AstraZeneca Covid-19 vaccine for people under 55 years following the increase in the number of patients suffering from blood clots.
In Canada, Manitoba, and Quebec provinces were the first ones to heed the new National Advisory Committee on Immunization and Health (NACI) guidelines with each region responsible for its immunization program.
"There is substantial uncertainty about the benefits of providing AstraZeneca vaccines to adults less than 55 years of age," Canada's deputy chief public health officer Howard Njoo told a news conference.
"At this time, we are pausing the use of AstraZeneca vaccine to adults less than 55 years of age, pending further risk-benefit analysis," Njoo said.
The Canadian medical officials, therefore, asked the people who have received AstraZeneca shots in the last 20 Days to consult a doctor.
According to Health Canada and NACI doctors, the manufacturer should conduct a detailed assessment of the benefits and risks of the vaccine by age and sex.
"To date, no cases of (blot clots) have been reported in Canada," Health Canada chief medical officer Supriya Sharma said.
"However, through our ongoing international collaboration, Health Canada has become aware that additional cases of these events have been reported in Europe," she said.
The AstraZeneca vaccine was approved for use in Canada in February alongside Johnson & Johnson, Pfizer, BioNTech, and Moderna shots.